Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure

Inclusion Criteria: * Able to provide informed consent for participation in the study, either by the participant themselves or by the legally acceptable representative (LAR) * Virological diagnosis of SARS-CoV-2 infection (PCR) * Acute respiratory distress syndrome (ARDS) not due to cardiac causes * Receiving mechanical ventilation Exclusion Criteria: * Severe comorbidity with life expectancy \<3 months according to investigators assessment * Currently receiving extracorporeal membrane oxygenation (ECMO) * Patients with established positive bacterial blood cultures prior to enrollment or suspicion of superimposed bacterial pneumonia * Patients with diagnosed significant pulmonary embolism or deep vein thrombosis in the previous 3 months * Patients who have been intubated for more than 48 hours * Known hypersensitivity to dimethyl sulfoxide (DMSO) or to porcine or bovine proteins * Acute co-morbidity within 7 days before inclusion such as stroke * History of severe chronic history of heart disease, recent myocardial infarction or unstable angina, lung disease (requiring home oxygen), pulmonary hypertension, or liver comorbidities * Malignancy that requires treatment in the previous two years (excluding non-melanoma skin malignancies treated by excision, or cryotherapy) * History of immunosuppression (immunomodulators or anti-rejection drugs in past year, or active disease, autoimmune disease on treatment, transplant recipients) or anaphylaxis * Refusal of blood products * Severe co-morbidity/co-morbidities which in the opinion of the investigators would compromise safety assessments * Pregnant or breast-feeding * Actively participating on another trial of an investigational agent for ARDS * Unacceptable laboratory blood tests for alanine aminotransferase (ALT)/aspartate aminotransferase (AST), neutrophils, or platelets